DE4229878A1 - Oxytocin for treatment of juvenile type I diabetes mellitus - increases prodn of tyrosine and adrenalin, necessary for glycogen mobilisation - Google Patents

Oxytocin for treatment of juvenile type I diabetes mellitus - increases prodn of tyrosine and adrenalin, necessary for glycogen mobilisation

Info

Publication number
DE4229878A1
DE4229878A1 DE4229878A DE4229878A DE4229878A1 DE 4229878 A1 DE4229878 A1 DE 4229878A1 DE 4229878 A DE4229878 A DE 4229878A DE 4229878 A DE4229878 A DE 4229878A DE 4229878 A1 DE4229878 A1 DE 4229878A1
Authority
DE
Germany
Prior art keywords
oxytocin
tyrosine
adrenalin
treatment
diabetes mellitus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE4229878A
Other languages
German (de)
Inventor
Des Erfinders Auf Nennung Verzicht
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KNAUF SIEGFRIED 06567 BAD FRANKENHAUSEN DE
Original Assignee
KNAUF SIEGFRIED 06567 BAD FRANKENHAUSEN DE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KNAUF SIEGFRIED 06567 BAD FRANKENHAUSEN DE filed Critical KNAUF SIEGFRIED 06567 BAD FRANKENHAUSEN DE
Priority to DE4229878A priority Critical patent/DE4229878A1/en
Publication of DE4229878A1 publication Critical patent/DE4229878A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The new medicament "Oxytocin" is for the treatment of diabetes mellitus type I patients who have none or insufficient oxytocin in the blood. The presumption that the low sugar level owing to a low adrenalin level is caused by an insufficient production of tyrosine. Tyrosine production is dependent on oxytocin. Therefore administration of oxytocin will produce tyrosine and hence adrenalin. Adrenalin should then mobilise glycogen for an increase in the blood sugar level causing the secretion of insulin. USE - Oxytocin is used for the treatment of juvenile type I diabetes mellitus. The blood sugar level is thereby increased to 80 to 120 mg/100 ml so that insulin is produced for the removal of blood glucose.

Description

Zur Zeit gibt es zwei Typen von Zuckerkrankheiten, Diabetes mellitus Typ 1und Diabetes mellitus Typ 2. Typ 1 tritt in jun­ gen Jahren auf, hat einen schnellen Beginn und ist nach kür­ zester Zeit nur durch Insulin, das täglich gespritzt werden muß, behandelbar. Die Patienten vom Typ 1 sind fast ausnahmslos schlank. Die Diabetiker vom Typ 2 sind meißt übergewichtig. Der Typ 2 tritt erst ab dem 40. Lebensjahr auf. Er entwickelt sich schleichend und wird häufig erst an seinen Folgen erkannt. Als Behandlung ist meist eine strenge Diät ausreichend, als zweite Stufe gibt es Tabletten, die den Blutzucker senken und nur in seltenen Fällen muß Insulin gespritzt werden.There are currently two types of diabetes, diabetes Type 1 mellitus and type 2 diabetes mellitus. Type 1 occurs in jun years, has a quick start and is short zester time only by insulin that are injected daily must be treatable. Type 1 patients are almost without exception slim. Type 2 diabetics are mostly overweight. Type 2 only occurs from the age of 40. He developes creeping and is often only recognized by its consequences. A strict diet is usually sufficient as treatment second stage there are tablets that lower blood sugar and only rarely does insulin need to be injected.

Der juvenile Diabetes Typ 1 wird in den meisten Fällen durch eine Selbstzerstörung der hormonproduzierenden Zellen der Bauchspeicheldrüse oder durch Virusinfektionen verursacht. Es kann auch eine Fehlsteuerung der Körperabwehr sein. Ich gehe davon aus, das ein großer Teil der Zuckerkranken Typ 1, kein oder zuwenig Oxytocin im Blut haben. Denn bei Typ 1 wird erwähnt, das es zum Unterzucker kommt. Nach meiner Mei­ nung wird der Unterzucker dadurch verursacht, das kein Adrena­ lin aus dem Nebennierenmark ausgeschüttet wird. Die Muttersub­ stanz von Adrenalin ist das Tyrosin, ohne Tyrosin kein Adrena­ lin. Und ist kein Adrenalin vorhanden sinkt der Blutzucker­ spiegel immer weiter ab. Voraussetzung für die Bildung der Aminosäure Tyrosin im Nebennierenmark, ist Oxytocin, was an dem Nebennierenmark die Bildung von Tyrosin auslöst. Ist der Blutzuckerspiegel im Blut über 80 mg/100 ml angestiegen, wird aus der Bauchspeicheldrüse das Hormon Insulin ausgeschüttet das in der Lage ist, die Glukose aus dem Blut zu entfernen. Der Patient mit Unterzucker würde auch bei Nahrungsaufnahme kaum über 80 mg/ 100 ml Blutzuckerwerte kommen, somit würde also nur schwach oder keine Sekretion von Insulin erfolgen. Juvenile type 1 diabetes is in most cases a self destruction of the hormone producing cells of the Pancreas or caused by viral infections. It can also be a malfunction of the body's defenses. I assume that a large part of the diabetic Type 1, have no or too little oxytocin in the blood. Because with type 1 it is mentioned that hypoglycemia occurs. After my Mei The hypoglycemia is caused by the fact that there is no adrena lin is released from the adrenal medulla. The mother sub The adrenaline punch is tyrosine, without tyrosine there is no adrenaline lin. And if there is no adrenaline, the blood sugar drops mirror more and more. Prerequisite for the formation of the Amino acid tyrosine in the adrenal medulla, what is oxytocin the adrenal medulla triggers the formation of tyrosine. If the blood sugar level has risen above 80 mg / 100 ml, the hormone insulin is released from the pancreas that is able to remove the glucose from the blood. The patient with hypoglycemia would also eat barely over 80 mg / 100 ml blood sugar levels, so would therefore only a weak or no secretion of insulin takes place.  

Es kommt somit auch nur wenig Zucker in die Depots. Das ist der Grund dafür das diese Menschen faßt ausnahmslos schlank sind.This means that there is little sugar in the depots. This is the reason why these people fit slim without exception are.

Literaturnachweis Prof. Dr. med. habil. Harald Aurich Laboratorium des Lebens Ergebnisse und Probleme der Biochemie Urania Verlag Leipzig- Jena Berlin 1. Auflage 1971 Seite 216-218 Ratgeber Hormone Dr. med. Andreas Geißler Roever Humboldt Taschenbuchverlag Jacobi KG München S. 48-58 Der im Patentanspruch 1 angegebenen Erfindung liegt das Pro­ blem zugrunde, den Zuckergehalt des Blutes wieder konstant in den Normbereich zwischen 80 und 100 mg/100 ml zu bringen bei den Patienten des Typ 1.Bibliography Prof. Dr. med. habil. Harald Aurich Laboratory of Life Results and problems of the biochemistry Urania Verlag Leipzig- Jena Berlin 1st edition 1971 page 216-218 Guide to hormones Dr. med. Andreas Geissler Roever Humboldt Taschenbuchverlag Jacobi KG Munich pp. 48-58 The invention specified in claim 1 is the pro underlying, the sugar content of the blood constant again in the normal range between 80 and 100 mg / 100 ml bring in type 1 patients.

Dieses Problem wird durch Gabe von Oxytocin erreicht. Damit wird Tyrosin im Nebennierenmark wieder gebildet, das Voraus­ setzung zur Bildung von Adrenalin ist.This problem is achieved by administration of oxytocin. In order to tyrosine is regenerated in the adrenal medulla, the advance to build adrenaline.

Die erreichten Vorteile liegen darin, das ein konstanter Blutzuckerspiegel von 80 bis 120 mg/100 ml wieder erreicht wird. Es kommt somit nicht mehr zum Unterzucker bei den Pa­ tienten, weil Adrenalin wieder gebildet wird, daß bei Ab­ sinken der Blutzuckerwerte von dem Nebennierenmark ausge­ schieden wird. Das Adrenalin mobilisiert dann wieder Glyko­ gen, so das der Blutzuckerspiegel wieder normalisiert wird. Es muß somit kein Insulin mehr gespritzt werden und es kommt auch nicht mehr zum gefürchteten Unterzucker, den man auch beim Spritzen von Insulin bekommen kann, wenn vorher keine Nahrungsaufnahme erfolgte.The benefits achieved are constant Blood sugar levels of 80 to 120 mg / 100 ml reached again becomes. The Pa no longer has low sugar tient because adrenaline is re-formed that Ab blood sugar levels decrease from the adrenal medulla will be divorced. The adrenaline then mobilizes glyco again gene, so that the blood sugar level is normalized again. It is therefore no longer necessary to inject insulin and it also no longer comes to the dreaded hypoglycemia, which one can also get insulin injections if before no food was taken.

Formel von OxytocinFormula of oxytocin

Claims (1)

Neues Medikament "Oxytocin" zur Bekämpfung der Zucker­ krankheit Typ 1, dadurch gekennzeichnet, das dieses nur bei Menschen auftritt, die kein oder zuwe­ nig Oxytocin im Blut haben.New drug "Oxytocin" to combat type 1 sugar disease, characterized in that this only occurs in people who have no or too little oxytocin in their blood.
DE4229878A 1992-09-04 1992-09-04 Oxytocin for treatment of juvenile type I diabetes mellitus - increases prodn of tyrosine and adrenalin, necessary for glycogen mobilisation Withdrawn DE4229878A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE4229878A DE4229878A1 (en) 1992-09-04 1992-09-04 Oxytocin for treatment of juvenile type I diabetes mellitus - increases prodn of tyrosine and adrenalin, necessary for glycogen mobilisation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4229878A DE4229878A1 (en) 1992-09-04 1992-09-04 Oxytocin for treatment of juvenile type I diabetes mellitus - increases prodn of tyrosine and adrenalin, necessary for glycogen mobilisation

Publications (1)

Publication Number Publication Date
DE4229878A1 true DE4229878A1 (en) 1994-03-10

Family

ID=6467413

Family Applications (1)

Application Number Title Priority Date Filing Date
DE4229878A Withdrawn DE4229878A1 (en) 1992-09-04 1992-09-04 Oxytocin for treatment of juvenile type I diabetes mellitus - increases prodn of tyrosine and adrenalin, necessary for glycogen mobilisation

Country Status (1)

Country Link
DE (1) DE4229878A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7405200B2 (en) * 2001-02-28 2008-07-29 Uvnaes-Moberg Kerstin Use of oxytocin for the preparation of a pharmaceutical composition against cancer in situ and cervicitis
RU2544462C1 (en) * 2013-11-29 2015-03-20 Федеральное государственное бюджетное учреждение "Государственный научный центр Российской Федерации-Федеральный медицинский биофизический центр имени А.И. Бурназяна Федерального медико-биологического агентства" (ФГБУ "ГНЦ ФМБЦ им. А.И. Бурназяна ФМБА России") Method for preventing acute pancreatitis following abdominal surgeries

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FORTH, W. et al.: Pharmakologie und Toxikologie, B-I-Wiss. Verlag, Mannheim 1988, 5. Aufl., S. 407-409 *
LANG, F.: Pathophysiologie, Pathobiochemie, Enke, Stuttgart 1983, S. 362-364 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7405200B2 (en) * 2001-02-28 2008-07-29 Uvnaes-Moberg Kerstin Use of oxytocin for the preparation of a pharmaceutical composition against cancer in situ and cervicitis
RU2544462C1 (en) * 2013-11-29 2015-03-20 Федеральное государственное бюджетное учреждение "Государственный научный центр Российской Федерации-Федеральный медицинский биофизический центр имени А.И. Бурназяна Федерального медико-биологического агентства" (ФГБУ "ГНЦ ФМБЦ им. А.И. Бурназяна ФМБА России") Method for preventing acute pancreatitis following abdominal surgeries

Similar Documents

Publication Publication Date Title
Gregorio et al. Therapeutical concentrations of tolbutamide, glibenclamide, gliclazide and gliquidone at different glucose levels: in vitro effects on pancreatic A-and B-cell function
Buchwald et al. Treatment of a type II diabetic by a totally implantable insulin infusion device
Surwit et al. Stress, behavior, and glucose control in diabetes mellitus
Vriesendorp et al. Hypoglycemia and strict glycemic control in critically ill patients
Sacco et al. Management of intracranial pressure: part I: pharmacologic interventions
Tamborlane et al. Insulin pump therapy in childhood diabetes mellitus: guidelines for use
EP0339054B1 (en) Mixture of substances for stabilyzing metabolism
Heller et al. Hypoglycaemia in diabetes
Balodimos et al. Hypoglycemic insulin reactions without warning symptoms
DE4229878A1 (en) Oxytocin for treatment of juvenile type I diabetes mellitus - increases prodn of tyrosine and adrenalin, necessary for glycogen mobilisation
Hussain et al. Hyperinsulinaemic hypoglycaemia in preterm neonates
Adam et al. Model for the investigation of intractable hypoglycemia: Insulin-glucose interrelationships during steady state infusions
Takahashi et al. A survey of insulin‐dependent diabetes—part i: therapies and devices
McCrimmon Remembrance of things past: The consequences of recurrent hypoglycaemia in diabetes
Perren et al. Spinal cord lesion after long-term intrathecal clonidine and bupivacaine treatment for the management of intractable pain
Pincus et al. Effect of rate of injection of alloxan on development of diabetes in rabbits.
GELLER et al. Insulin-resistant diabetes precipitated by cortisone and reversed by nitrogen mustard
Fernandez-Castaner et al. Somatostatin and counterregulatory hormone responses to hypoglycaemia in diabetics with and without autonomic neuropathy
DE60308531T2 (en) Signaling device for facilitating the administration of medical preparations
Hell et al. Influence of the vagus and splanchnic nerves on insulin secretion and glycemia
CONN Endocrine regulation of the blood sugar
Horvath et al. The effects of large doses of intravenous insulin in psychotic nondiabetic patients
Parodi et al. Long-term treatment of diabetes with glipizide
Malone Lessons for pediatricians from the diabetes control and complications trial
Santiago et al. Status of pancreatic transplants and mechanical devices for blood glucose control in diabetes

Legal Events

Date Code Title Description
OP8 Request for examination as to paragraph 44 patent law
8122 Nonbinding interest in granting licences declared
8139 Disposal/non-payment of the annual fee